Citi raised the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $12 and keeps a Neutral rating on the shares. The company reported Q4 earnings and reiterated its corporate plans for a year focused on clinical stage execution, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $50 from $60 at Wells Fargo
- Intellia Therapeutics price target lowered to $26 from $55 at Barclays
- Intellia Therapeutics: Hold Rating Amid Long-Term Prospects and Strategic Restructuring
- Intellia Therapeutics Reports 2024 Financial Results and Progress
- Intellia Therapeutics’ Earnings Call: Progress and Challenges